Loading
Quantitative Imaging / Fluorescence Imaging · Journal article
Biofilm · August 18, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study develops a standardized image-processing framework to objectively quantify biofilm-associated matrix signals from wound blotting (WBDK) and bacterial fluorescence from MolecuLight i:X in 103 chronic wounds. Quantitative WBDK intensity demonstrated strong discriminative ability (AUC 0.921, 95% CI 0.878–0.975) for predicting 90-day wound healing, substantially outperforming fluorescence intensity (AUC 0.732), with adjusted non-healing risk rising 2.05-fold per standard deviation increase in WBDK intensity. While the method shows promise for objective biofilm assessment, the retrospective design, single-centre setting, and absence of independent validation limit immediate clinical translation.
Retrospective cohort study with standardized image-processing algorithm development. 103 chronic wound cases; setting (hospital, outpatient, or mixed), specific wound aetiologies, and key eligibility criteria not detailed in provided text.. Intervention: Standardized quantitative image analysis of WBDK (Alcian blue staining intensity) and MolecuLight i:X (bacterial fluorescence intensity).. Compared with: WBDK intensity compared directly against MolecuLight i:X fluorescence intensity for prognostic performance; both compared against 90-day wound healing outcome.. n = 103. National Taiwan University Hospital and National Tsing Hua University (Taiwan); single-centre study..
WBDK intensity achieved AUC 0.921 (95% CI 0.878–0.975) for predicting 90-day wound healing. MolecuLight i:X fluorescence intensity showed moderate predictive performance with AUC 0.732 (95% CI 0.625–0.839). Adjusted risk ratio for non-healing was 2.05 per one–standard deviation increase in WBDK intensity.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work provides an objective quantification method for bedside biofilm assessment that could improve reproducibility and standardization of chronic wound risk stratification beyond subjective visual grading. However, prospective validation in a separate cohort and comparison with established wound-healing predictors are needed before integration into clinical decision-making algorithms.
Retrospective cohort study with objective image-analysis methods showing WBDK biofilm-matrix quantification achieves AUC 0.921 for 90-day wound healing, but lacks prospective validation, control arm, and real-world implementation testing.
As stated by the source record.
Quoted from the source exactly as published.
This work provides an objective quantification method for bedside biofilm assessment that could improve reproducibility and standardization of chronic wound risk stratification beyond subjective visual grading. However, prospective validation in a separate cohort and comparison with established wound-healing predictors are needed before integration into clinical decision-making algorithms.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Bacterial burden and biofilm-associated wound pathology are important contributors to delayed wound healing. However, conventional diagnostic methods are time-consuming and do not provide real-time, objective quantification of bacterial fluorescence or biofilm-associated wound-bed matrix signals, limiting their value for timely clinical decision-making. Bedside technologies such as MolecuLight i:X and the Wound Biofilm Detection Kit (WBDK) enable rapid visualization of bacterial fluorescence and Alcian blue-positive wound-blotting signals, respectively, but their interpretation largely depends on subjective visual assessment. This retrospective cohort study developed a standardized image-analysis approach to objectively quantify bacterial fluorescence signals detected by MolecuLight i:X and Alcian blue-positive wound-blotting matrix signals detected by WBDK. Clinical images from 103 chronic wound cases were retrospectively analyzed. Image-processing protocols were established to quantify fluorescence intensity as a surrogate marker of bacterial burden and WBDK staining intensity as a quantitative measure of biofilm-associated matrix signals. These quantitative metrics were evaluated for their associations with 90-day wound healing outcomes. WBDK intensity demonstrated strong discriminative ability for predicting 90-day wound healing (AUC = 0.921, 95% CI 0.878-0.975). In contrast, MolecuLight i:X fluorescence intensity showed moderate predictive performance (AUC = 0.732, 95% CI 0.625-0.839). Per one-standard deviation increase, the adjusted risk ratio for non-healing was 2.05 for WBDK intensity and 1.41 for fluorescence intensity. Objective quantification of WBDK-derived biofilm-associated matrix signals provides stronger prognostic information than bacterial fluorescence intensity alone and may enable more reproducible stratification of chronic wounds.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.